# Challenges and opportunities in proximity-driven exciton-spin engineering in van der Waals heterostructures

Preprint · Mushir Thodika, Dimitar Pashov, Igor Zutic, Mark van Schilfgaarde, Swagata Acharya

- Archive id: arxiv:2509.21956
- Published: 2025-09-26
- arXiv: https://arxiv.org/abs/2509.21956
- Source URL: https://arxiv.org/abs/2509.21956
- PDF: https://arxiv.org/pdf/2509.21956
- Provenance: arxiv

## Abstract

van der Waals heterostructures consisting of transition metal dichalcogenides (TMDs) and two-dimensional (2D) magnets offer a versatile platform to study the coexistence and transformation of different excitons. By focusing on TMD WSe$\_2$ and 2D magnetic CrI$\_3$, as a bilayer WSe$\_2$/CrI$\_3$ and a trilayer CrI$\_3$/WSe$\_2$/CrI$\_3$, we provide their description using a parameter-free, high-fidelity many-body perturbation theory. This ab initio approach allows us to elucidate the character of magnetic Frenkel excitons in CrI3 and how the nonmagnetic Wannier-Mott excitons in WSe2 are modified by the proximity of CrI3. We reveal novel proximity-induced interlayer excitons in these heterostructures. In contrast to the sensitivity of proximity-induced modifications of excitons in WSe$\_2$, which depend on the interfacial details, the interlayer magnetic excitons are remarkably robust and are present across the different stacking configurations between WSe$\_2$ and CrI$\_3$, simplifying their experimental demonstration. These findings suggest unexplored opportunities for information transduction using magnetic excitons and integrating photonics, electronics, and spintronics in proximitized materials.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

Topics: [2D Materials & Van der Waals Heterostructures](https://space-kitty.com/topics/2d-materials)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.